

## **Michael David Banov, M.D. - Curriculum Vitae**

---

### **BOARD CERTIFICATION**

American Board of Psychiatry and Neurology-Re-certification September 2006

American Board of Psychiatry and Neurology-February 1995

American Board of Adolescent Psychiatry-June 1997

Certification in Addiction Psychiatry by American Board of Psychiatry and Neurology- July 1998

### **RESEARCH CERTIFICATION**

Certified Clinical Research Investigator (CCRI). Certification by Association of Clinical Research Professionals (ACRP), 2002-2010

### **OFFICE ADDRESS**

Northwest Behavioral Medicine and Northwest Behavioral Research Center

108 Margaret Avenue

Marietta, GA 30060

Phone (770) 422-2009 Fax (770) 428-0330

Northwest Behavioral Medicine and Northwest Behavioral Research Center

11755 Pointe Place, Suite A-1

Roswell, GA 30076

Phone (770) 667-1264 Fax (770) 667-2238

### **CURRENT POSITION**

Medical Director, Northwest Behavioral Medicine

Adolescent, Adult, and Geriatric Psychiatry

Marietta and Roswell, GA - March 1994 to present

Medical Director, Northwest Behavioral Research Center

Marietta, GA - March 1996 to present

*Michael D. Banov, M.D.*

Medical Director and President, Psychsource LLC - A not-for-profit organization committed to providing mental health resource information to the community  
Alpharetta, GA - June 1999 to present

Physician Advisory Board-Skyland Trail Mental Health Treatment Center  
Atlanta, GA – 2003 to present

### **HOSPITAL AFFILIATIONS**

Kennestone Hospital - June 1994 to present  
Marietta, GA

Ridgeview Institute - March 1994 to present  
Smyrna, GA

Brawner North Hospital - March 1994 to June 1996  
Smyrna, GA

Northside Hospital - June 1995 to June 1996  
Atlanta, GA

Charter-Peachford Hospital- June 1995-June 2002  
Atlanta, GA

### **POSITIONS HELD**

Chief, Department of Psychiatry - August 1997-June 1999  
Kennestone Hospital, Marietta, GA

Director of Medical Education, Ridgeview Institute - March 1994 to October 1998  
Atlanta, GA

Clinical Instructor in Psychiatry - July 1993 to December 1993  
Harvard Medical School, Boston, MA

Assistant Attending Psychiatrist - July 1993 to December 1993  
McLean Hospital, Belmont, MA

### **POSTGRADUATE TRAINING**

Chief Resident, Psychotic Disorders Program, McLean Hospital, Consolidated  
Department of Psychiatry, Harvard Medical School - 1992 to 1993

Updated 03-May- 2010

*Michael D. Banov, M.D.*

Consultation-Liaison Service, Massachusetts General Hospital, Boston, MA - 1992

Clinical Fellow in Adult Psychiatry, McLean Hospital, Consolidated Department of Psychiatry, Harvard Medical School - 1990 to 1993

Medical Internship in Internal Medicine, The University Hospital, Boston University Medical Center - 1989 to 1990

## **EDUCATION**

M.D. Emory University School of Medicine, Atlanta, GA - 1986 to 1989

Medical University of South Carolina, Charleston, SC - 1985 to 1986

A.B. Duke University, Durham, NC - Religion - 1984

Tel Aviv University, Tel Aviv, Israel - 1980

## **HONORS**

The Dr. Henry P&M Page Durkee Laughlin Fellowship Award - 1993

Harry C. and Maida Solomon Award for most outstanding research, Harvard Medical School Consolidated Department of Psychiatry - 1993

Letter of academic achievement, Medical University of South Carolina - 1986

Magna Cum Laude, Duke University - 1984

Class Honors, Dean's List, Duke University - 1981 to 1982

## **PROFESSIONAL EXPERIENCE**

Psychiatric Consultant/Doctor on Call - 1991 to 1993

Human Resource Institute, Boston, MA

Carney Hospital, Boston, MA

Norwood Hospital, Norwood, MA

Waltham-Weston Hospital, Waltham, MA

Psychopharmacology Consultant to geriatric services and day program for chronically mentally ill patients, Tri-City Mental Health and Retardation Center, Everett, MA - 1992 to 1993

Updated 03-May- 2010

*Michael D. Banov, M.D.*

## **LICENSURE**

Georgia Composite State Board of Medical Examiners-1994 to present. License No. 037945

Commonwealth of Massachusetts Board of Registration in Medicine-1990 to 1996

Diplomate of National Board of Medical Examiners-1990

## **PROFESSIONAL ACTIVITIES**

Lawyer Assistance Committee, State Bar of Georgia - August 2004 - present

Georgia Psychiatric Physicians Association, Economic Affairs Committee - August 2004-present

Credentialing Committee, Kennestone Hospital - August 1997- June 2001

Utilization Review Committee, Kennestone Hospital - June 1995 - June 2001

Chairman, Continuing Medical Education, Ridgeview Institute - March 1995 - October 1998

Outcomes Research Committee, Ridgeview Institute - March 1995-October 1998

Drug Evaluation Committee, Ridgeview Institute - March 1995-August 1997

Economic Affairs Committee, Georgia Psychiatric Physicians Association- February 1994 to June 1996

Medical Records Committee, Brawner Hospital-May 1994-June 1996

Secretary-Treasurer, McLean Residents' Association - 1990 to 1993

McLean Psychopharmacology Journal Club - 1990 to 1993

President, Super Health 2000 - An organization of over 100 health professionals who educate school and community groups on 15 health topics - 1985 to 1986

## **PUBLICATIONS**

Banov MD, Kulick, AR, Oepen G, Pope HG. *A New Identity for Misidentification Syndromes*. *Compr Psychiatry*, 1993; 34:114-117.

Updated 03-May- 2010

*Michael D. Banov, M.D.*

Banov MD, Tohen M, Friedberg J. *High Risk of Eosinophilia in Women Treated with Clozapine.* J Clin Psychiatry, 1993; 54:466-69.

Banov MD, Zarate CA, Scialabba D, Tohen M, Wines JD, Kolbrener M, Kim JW, Cole JO. *Clozapine Therapy in Refractory Affective Disorders: Polarity Predicts Response in Long-Term Follow-Up.* J Clin Psychiatry, 1994; 55:295-300.

Sachs GS, Lafer B, Stoll AL, Banov MD, Thibault AB, Tohen M, Rosenbaum JF. *A Double-Blind Trial of Bupropion Versus Desipramine for Bipolar Depression.* J Clin Psychiatry, 1994; 55:391-93.

Banov MD. *Stay Tuned: Recognizing and Treating Attention Deficit Hyperactivity Disorder in Adults.* Insight, 1994; 15:28-31.

Stoll AL, Banov MD, Kolbrener M, Mayer PV, Tohen M, Strakowski A, Castillo J, Suppes P, Cohen BM. *Neurological Factors Predict a Favorable Valproate Response in Bipolar Disorder.* J Clin Psychopharmacology, 1994; 14(5):311-3

Banov, MD. *Brain Medicines: Recent Developments in Psychopharmacology.* Insight, 1995; 16:24-7.

Zarate CA, Tohen M, Banov MD, Weiss MK, Cole JO. *Is Clozapine a Mood Stabilizer?* J Clin Psychiatry, 1995; 56:108-112.

Pillay SS, Stoll AL, Weiss MK, Tohen M, Zarate CA, Banov MD, Cole JO. *EEG Abnormalities Before Clozapine Therapy Predict a Good Clinical Response to Clozapine.* Ann Clin Psychiatry, 1996; 8(1):1-5.

Banov MD. *Again & Again: Treatment Strategies for Obsessive-Compulsive Spectrum Disorders.* Insight, 1997;18:26-9.

Banov MD. *Improved Outcome in Fluvoxamine Treated Patients With SSRI-Induced Sexual Dysfunction.* J Clin Psychiatry, 1999; 60(12): 866-868

Green, AI, Tohen, M, Patel, JK, et al. *Clozapine in the Treatment of Refractory Psychotic Mania.* Am J Psychiatry, 2000; 157(6): 982-986.

Tohen M, Jacobs TG, Grundy SL, Banov MC, McElroy SL, Janica PG, Zhang F, Toma V, Francis J, Sanger T, Tollefson GD, Breier A: *Efficacy of olanzapine in*

*Michael D. Banov, M.D.*

*acute bipolar mania: a double-blind, placebo-controlled study.* Arch Gen Psychiatry 2000; 57:841-849

Mauricio Tohen, Joseph R. Calabrese, Gary S. Sachs, Michael D. Banov, Holland C. Detke, Richard Risser, Robert W. Baker, James C.-Y. Chou, and Charles L. Bowden *Randomized, Placebo-Controlled Trial of Olanzapine as Maintenance Therapy in Patients With Bipolar I Disorder Responding to Acute Treatment With Olanzapine* Am J Psychiatry 2006 163: 247-256

Bortnick B, Elkhaili E, Datto C, Banov M. *Efficacy and tolerability of Extended Quetiapine XR Monotherapy in major Depressive Disorder: A Placebo-Controlled, Randomized Study.* Journal of Affective Disorders. Accepted for Publication. 2010.

Banov, MD. *Taking Antidepressants: Your Comprehensive Guide to Starting, Staying On, and Safely Quitting.* Sunrise River Press. July 2010.

## **CLINICAL PSYCHOPHARMACOLOGY RESEARCH**

### **Principal Investigator:**

A Double-Blind, Placebo-controlled Study of XXX as Adjunctive Therapy in Major Depressive Disorder. August 2009 to Present

A randomized, Double-Blind, Parallel Group to Compare Discontinuation Symptoms in Abrupt Discontinuation versus a 1-week Tapering Regimen in Subjects With Major Depressive Disorder Treated for 24 Weeks With Open-label XX. September 2009 to Present

A Phase 2, Multi-Center, Randomized, Double-blind, Placebo-Controlled, Adaptive Study of the Safety and Efficacy of XXX in Adults with Alcohol Dependence. February 2009 to Present

A Phase 4, Randomized, Double-Blind, Multi-center, Placebo-controlled, Parallel Group Study Evaluating the Safety and Efficacy of XXX on Executive Function (Self-regulation) Behaviors in Adults with Attention-Deficit/Hyperactivity Disorder

Updated 03-May- 2010

*Michael D. Banov, M.D.*

(ADHD) Reporting Clinically Significant Impairment of Real-world Executive Function Behavior. May 2010 to Present

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study Evaluating the Efficacy and Safety of XXX in Posttraumatic Stress Disorder (PTSD). November 2009 to Present

A Double-Blind, Efficacy and Safety Study of XX versus Placebo in the Treatment of Children and Adolescents with Major Depressive Disorder May 2010 to Present

A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of XX as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder March 2010 to Present

A Phase 3, Double-blind, Randomized, Multi-center, Placebo controlled, Dose Optimization Study Evaluating the Tolerability and Efficacy of AM and PM Once Daily Dosing with Extended-release XX in Children Aged 6 - 12 with a Diagnosis of Attention-Deficit/Hyperactivity Disorder October 2009 to Present

A Study to Assess the Long-Term Efficacy and Safety of XX and XX Combination Versus XX only in the Relapse Prevention of Stabilized Patients with Treatment-Resistant Depression August 2009 to Present

A Placebo-controlled, Double-Blind, Parallel-group, Individualized Dosing Study Optimizing Treatment of adults with Attention Deficit Hyperactivity Disorder to an Effective Response with XXX May 2009 to May 2010

A Phase IV, Double-Blind, Multi-Center, Placebo-Controlled, Randomized Withdrawal, Safety and Efficacy Study of XXX in Adults Ages 18-55 with Attention-Deficit/Hyperactivity Disorder (ADHD) March 2009 to April 2010

A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety and Tolerability of XXX Compared to Placebo in Female Subjects, Diagnosed with Major Depressive Disorder. November 2008 to April 2010

Updated 03-May- 2010

*Michael D. Banov, M.D.*

A Phase 3, Randomized, Double-blind, Placebo Controlled, Parallel Group, 10-Week Study Evaluating the Efficacy and Safety of XXX for the Treatment of Generalized Anxiety Disorder. August 2007 to May 2009

A 52-Week Open-Label Safety Study of XXX in Subjects with Generalized Anxiety Disorder. September 2007 to May 2009

A Phase IIIb, randomized, double-blind, Multicenter, parallel-group, placebo-controlled, dose optimization study, designed to evaluate the efficacy and safety of XXX in adolescents aged 13-17 years with Attention-Deficit/Hyperactivity Disorder (ADHD), October 2007- September 2008.

A Phase IIIB, long-term, open-label, multicenter, extension study designed to evaluate the safety and efficacy of XXX in adolescents aged 13-17 years with Attention-Deficit/Hyperactivity Disorder (ADHD), October 2007- May 2010

An open-label trial measuring satisfaction and convenience of two formulations of XXX in subjects with a mood disorder. October 2007-March 2008.

A Phase III, Randomized, Double-blind, Multi-center, Placebo-controlled, Parallel-group, Forced Dose Titration, Safety and Efficacy Study of XXX in Adults with Attention-Deficit Hyperactivity Disorder (ADHD). March 2005-November 2007.

XXX Combination Versus XXX in the Treatment of Bipolar I Depression. March 2005-July 2007.

An 8-Week, Open-Label Study to Characterize the Response to XXX Treatment at Dosages up to XXX in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder With an Open-Ended Extension Period, November 2005-February 2007.

A Multi-center, Double-blind, Randomized-withdrawal, Parallel-group, Placebo-controlled Phase III Study of the Efficacy and Safety of XXX as Monotherapy in the Maintenance Treatment of Patients with Major Depressive Disorder Following an Open-Label Stabilization Period, March 2006-August 2007.

A Multi-center, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of XXX as Monotherapy in the

Updated 03-May- 2010

*Michael D. Banov, M.D.*

Treatment of Adult Patients with Major Depressive Disorder, April 2006-August 2007.

A Six-Week, Double-Blind, Multi-center, Placebo-Controlled Study Evaluating the Efficacy and Safety of Flexible Doses of XXX in Outpatients with Bipolar I Depression, February 2006-June 2007.

Efficacy, Safety, and Tolerability of XXX in the Treatment of Children aged 6-17 years With ADHD-associated Insomnia. A Multi-center, Randomized, Double-Blind, Placebo-Controlled Study. March 2006-September 2006.

A randomized, double-blind, placebo-controlled, multi-center study of XXX in patients with opioid dependence. November 2006- February 2008.

A multi-center, double-blind, randomized, parallel-group, placebo-controlled Phase III study of the efficacy and safety of XXX SR as mono-therapy in the treatment of elderly patients with MDD, March 2007-May 2009.

A multi-center, double-blind, randomized, parallel-group, placebo-controlled Phase III study of the efficacy and safety of XXX SR as mono-therapy in the treatment of elderly patients with GAD, March 2007-June 2009.

A multicenter, randomized, 8-week double-blind acute phase followed by a 6-month continuation phase (open-label or double-blind) study to evaluate the efficacy, safety, and tolerability of XXX versus XXX in postmenopausal women with major depressive disorder. January 2007-September 2009.

A long-term, open-label, and single arm study of XXX 30mg, 50mg, or 70mg per day in adults with Attention Deficit Hyperactivity Disorder. July 2006-March 2008.

A 2-year, Prospective, Blinded-Rater, Open-Label, Active-Controlled, Multi-Center, Randomized Study of Long-Term Efficacy and Effectiveness Comparing XXX and XXX in Adults with Schizophrenia. May 2006-May 2009.

A Comparison of XXX Extended-Release VS. Placebo in the Treatment of Insomnia Associated With Generalized Anxiety Disorder (GAD) When Used Concomitantly With XXX. March 2006 to January 2008.

Updated 03-May- 2010

*Michael D. Banov, M.D.*

A Multi-center, Randomized, Parallel-group, Double-blind, Phase III Comparison of the Efficacy and Safety of XXX to Placebo When Used as Adjunct to Mood Stabilizers (XXX or XXX) in the Maintenance Treatment of bipolar I Disorder in Adult Patients. February 2004 to February 2007.

A Randomized, Double-Blind, Placebo Controlled, Multi-center Study To Evaluate The Efficacy, Safety, And Tolerability Of XXX In Patients With Generalized Anxiety. Start September 2005 to May 2008.

A multi-center, double-blind, randomized-withdrawal, parallel-group, placebo-controlled Phase III study of the efficacy and safety of XXX as monotherapy in the maintenance treatment of patients with Generalized Anxiety Disorder following an open-label stabilization period. November 2006 to August 2007.

A multi-center, double-blind, randomized, parallel-group, placebo-controlled phase III study of the efficacy and safety of XXX in combination with an antidepressant in the treatment of patients with major depressive disorder with inadequate response to an antidepressant treatment. November 2006-August 2007.

A Phase III, Randomized, Double-blind, Multi-center, placebo-controlled, parallel-group, forced dose titration, safety, and efficacy study of XXX in adults with Attention Deficit Hyperactivity Disorder. May 2006-Dec 2006.

An Eight-Week, Multinational, Multicenter, Randomized Double-blind, Placebo-controlled study, with XXXX as an Active Control to Evaluate the Efficacy, Safety and Tolerability of XXXX 100 mg in Elderly Patients with Major Depressive Disorder March 2007 to November 2007.

A Randomized Comparison of Outcomes in Patients with Treatment Resistant Depression who receive XXX therapy Administered at Different Amounts of Electrical Charge. August 2007 to February 2010.

A Randomized, Double-blind, Placebo Controlled Parallel Group Study to Evaluate the Safety and Efficacy of XXXX in Patients with Recurrent Major Depressive Disorder. July 2007 to July 2008.

Updated 03-May- 2010

*Michael D. Banov, M.D.*

A Multi-Center, Randomized, Double-Blind, Parallel-Group Fixed dose study of the Effect on Weight of XXXX versus XXXX in the Treatment of Outpatient with Schizophrenia. September 2006 to October 2008.

An 8 week Randomized Double-Blind Fixed Dose, Placebo-Controlled Parallel Group, Multicenter Study of the Efficacy, Safety and Tolerability of XXXX 25mg and 50 mg in the treatment of Major Depressive Disorder with an Open Label Extension. December 2006 to March 2008

An 8 week Randomized, Double blind, fixed dose, Placebo-Controlled, Parallel Group, Multi-Center Study of the Efficacy, Safety and Tolerability of XXX in the treatment of Insomnia Associated with Newly Diagnosed Major Depressive Disorder. February 2006 to July 2007.

A Phase II randomized double blind placebo controlled study to evaluate the Efficacy of XXXX in the treatment of Insomnia. March 2006 to December 2006.

A Multicenter, Randomized, Double Blind, Placebo Controlled Study of XXX in the Treatment of Patients with Bipolar I Disorder with Major Depressive Episode, June 2005-July 2006.

A 9-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Study of 500 Inpatients and Outpatients Meeting Diagnostic Criteria For a Mild to Moderate Manic or Mixed Episodes Associated with Bipolar I Disorder. October 2004 to March 2006.

A Randomized, Double-Blind, Placebo Controlled Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of XXX in Patients with Generalized Anxiety Disorder August 2005-May 2007.

A Randomized Double-Blind Parallel Group Placebo-Controlled Fixed Dose Study Evaluating the Efficacy and Safety of XXX in Subjects with Major Depressive Disorder. September 2004-October 2005.

A Multicenter, Double-Blind, Placebo-Controlled, Fixed- Dose, 8 week Evaluation of the Efficacy and Safety of XXX in the Treatment of Bipolar Disorder Patients Currently Experiencing a Major Depressive Episode. September 2004- October 2005.

Updated 03-May- 2010

*Michael D. Banov, M.D.*

A Multicenter, Double-Blind, Placebo-Controlled, Fixed- Dose, 8 week Evaluation of the Efficacy and Safety of XXX in the Treatment of Major Depression in Patients with Type II Bipolar Disorder. February 2003- October 2005.

A Multicenter, Randomized, Parallel-group, Double-Blind, Phase III Comparison of the Efficacy and Safety of XXX When Used as Adjunct to Mood Stabilizers in the Maintenance Treatment of Bipolar I Disorder in Adult Patients. March 2004- August 2005.

A Phase III, Randomized, Double Blind, Multicenter, Placebo Controlled, Parallel-Group, Forced Dose Titration, Safety and Efficacy Study of XXX in Adults with Attention Deficit Hyperactivity Disorder June 2005-September 2005

XXX versus XXX and Placebo in the Treatment of Mild to Moderate Mania Associated with Bipolar Disorder October 2004- November 2005.

XXX versus XXX in the Treatment of Bipolar I Disorder October 2003-October 2005.

An 8-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter, Fixed Dose Study Comparing the Efficacy and Safety of XXX or XXX to Placebo in Moderately to Severely Depressed Patients with Major Depressive Disorder. September 2002 to June 2003.

A Study of XXX plus XXX in Combination for Treatment-Resistant Depression without Psychotic Features. February 2002 to September 2005.

An Eight-week, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of 2 Doses of XXX and XXX in Subjects with Major Depressive Disorder. October 2001 to November 2002.

A 12-Month, Open-Label Study of XXX in Adults with Attention Deficit Hyperactivity Disorder. January 2002 to July 2004.

A Randomized, Double Blind, Placebo-controlled, Parallel-Group Study of XXX in Adults with Attention Deficit Hyperactivity Disorder. January 2002 to September 2002.

Updated 03-May- 2010

*Michael D. Banov, M.D.*

A randomized, double-blind, parallel-group, placebo-controlled, study evaluating efficacy and safety of XXX versus placebo in patients with Major Depressive Disorder. September 2001 to July 2002.

A double-blind, randomized, placebo-controlled, 3-month clinical trial of XXX and XXX in the treatment of Posttraumatic Stress Disorder. September 2001 to September 2002.

A randomized, double-blind, placebo-controlled, flexible dosage trial to evaluate the efficacy and tolerability of XXX in patients with Generalized Anxiety Disorder. August 2001 to July 2002.

A double-blind, placebo controlled, fixed-dosage study comparing the efficacy and tolerability of XXX and XXX to placebo in the treatment of Major Depressive Disorder with anxiety. March 2001 to September 2001.

A Six-Week, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Safety and Efficacy of 3 Doses of XXX and XXX in Subjects with Major Depression. June 2000 to January 2001.

Open-Label Combination of XXX and XXX in Major Depressive Disorder. February 2000 to June 2002.

A Phase III, Open-Label, Treatment-Switching Study from Orally Administered Antipsychotic Monotherapy to Orally Administered XXX Monotherapy in the Treatment of Chronic Schizophrenia and Schizoaffective Patients. November 1999-July 2000.

XXX Versus Placebo in the Prevention of Relapse in Bipolar Disorder. July 1999-March 2002.

A 12-Week, Randomized, Double-blind, Placebo Controlled, Flexible Dose Study of XXX in the Treatment of Generalized Social Anxiety Disorder. August 1999-February 2000.

A Multicenter, Open-Label, Long-Term, Safety and Efficacy Study of XXX Tablets Once Daily in Subjects With Schizophrenia or Other Psychotic Disorders. September 1998-September 1999.

Updated 03-May- 2010

*Michael D. Banov, M.D.*

A 12 week, Double-blind, Placebo controlled, parallel group study to assess the efficacy and tolerability of XXX in Patients suffering from Posttraumatic Stress Disorder (PTSD). January 1999-February 2000.

XXX Verses Placebo in the Treatment of Bipolar Disorder, Manic or Mixed. Eli Lilly. January 1998-November 1998.

XXX Experience with Safety and Tolerability (Quest). Zeneca Limited. August 1997-March 1998.

**Sub-investigator:**

XXX in Treatment of Schizophrenia, Schizoaffective, and Bipolar Disorder. Zeneca Limited. February 1997-July 1997.

XXX vs. XXX vs. Placebo in Inpatient Treatment of Melancholic Depression. Wyeth-Ayerst Laboratories. February 1997-July 1997.

Double-Blind Dose Comparison of IM XXX in Psychosis with Acute Agitation. Pfizer Pharmaceuticals. January 1997- July 1997.

**Additional Research Experience:**

McLean Hospital, Consolidated Department of Psychiatry, Harvard Medical School, Belmont, MA. 1992-1994.

Clozapine in Acute Mania - Prospective study to evaluate the safety and efficacy of clozapine in the treatment of refractory acute bipolar mania and psychotic features.

First Psychosis Project - Prospective study to determine characteristics, outcome and response to treatment of all first hospitalized psychotic patients.

Meta-analysis of Clozapine in the Treatment of Acute Psychosis - Literature review analysis of double-blind studies comparing clozapine to typical neuroleptics.

**PRESENTATIONS**

NCDEU Poster Presentation-*Antidepressant Activity of PRX-00023, a Novel, Selective Serotonin 1A Receptor Agonist, in Patients with GAD: Results of a*

*Michael D. Banov, M.D.*

*Double Blind, Placebo Controlled Study.* Karl Rickels, Sanjay Matthew, Michael Banov, Daniel Zimbhoff, et al. June 13, 2007.

*New Developments in Psychopharmacology.* Professional Education Series. Ridgeview Institute. June 17th and July 20th 2007.

*Psychiatry for the Non-Psychiatrist.* Georgia Academy of Family Physicians. 52nd Annual Scientific Assembly and Exhibition. November 3, 2000

*New Developments in Wakefulness Medications.* Continuing Medical Education Series. Summit Ridge Hospital. Lawrenceville, Georgia. October 19, 2000

*New Medications for Mental Illness.* NAMI-GA Convention. October 14, 2000

*Managing Social Anxiety Disorder.* Atlanta Steeplechase. SmithKline Beecham. April 15, 2000.

*Zyprexa Approved For Treatment of Acute Mania.* WSB-TV Interview. Atlanta GA, April 5, 2000

*Anticonvulsants in the Management of Bipolar Disorder.* Abbott Laboratories. Phillips Arena. Atlanta GA, November 15 1999.

*Anxiety Disorders.* WSTR-FM. "Steve and Vickie in the Morning". Atlanta, GA, October 6, 1999

*Social Anxiety Disorder.* WXIA-TV (NBC). Atlanta GA, October 5, 1999

*New Options For Managing Social Anxiety Disorder.* WSB-AM (CNN Radio). Atlanta GA, October 5, 1999

*New Directions in the Treatment of Bipolar Disorder.* Continuing Medical Education Series. Ridgeview Institute. March 3, 1999

*Community Discussion About Obsessive-Compulsive Disorder with Marc Summers.* Westin Atlanta North at Perimeter. February 25, 1999.

*Treatment Issues in Violent Mentally Ill Patients.* Clayton County Mental Health Center. Morganton NC, April 20, 1998.

*New Advances in Psychopharmacology.* Student Assistance Professionals Association, Atlanta, GA, February 18, 1998.

Updated 03-May- 2010

*Michael D. Banov, M.D.*

*Hypochondriasis.* WGNX-TV 46 News. September 1997.

*The Dangers of Huffing.* WGNX-TV 46 News. August 1997.

*Assessment and Treatment Strategies in Working with the Patient with Attention Deficit Hyperactivity Disorder.* Medical Association of Georgia, Scientific Assembly, Atlanta, GA. November 17, 1995.

*Recent Developments in Psychopharmacology.* Ridgeview Institute CME Tape Learning Series. October, 1995.

*Medicines in Psychiatry.* WSB Radio 750. August 1995.

*Diagnosing and Treating ADHD in Adults.* Ridgeview Institute, Seminars for Clinicians, Atlanta, GA. April 28, 1995.

*Seasonal Affective Disorder.* Ridgeview Institute, Family Learning Series, Atlanta, GA. January 26, 1995.

*Is Clozapine Monotherapy an Effective Mood Stabilizer?* Presented at American College of Neuropsychopharmacology, Honolulu, Hawaii, December 17, 1993.

*Clozapine Therapy in Refractory Affective Disorders: Polarity Predicts Response in Long-Term Follow-Up.* Presented at the American Psychiatric Association Annual Meeting, San Francisco, CA, May 24, 1993.

*Clozapine in Affective Disorders.* Psychopharmacology Series, Affective Disorders Program, McLean Hospital, May 6, 1993.

*Successful Use of Clozapine in Refractory Psychosis with Co-morbid Substance Abuse: A Long Term Follow-Up Study.* Harvard Medical School Consolidated Department of Psychiatry Research Day, April 21, 1993.

*Clozapine as Maintenance Therapy in Affective Illnesses.* Presented at The Boston Society of Neurology and Psychiatry, Cobb Assembly, March 25, 1993.

*Obsessive/Compulsive Symptoms in Psychotic Patients: Related or Distinct Entities?* Banov MD, Moderator, Clinical Case Conference. McLean Hospital Department of Postgraduate and Continuing Medical Education, January 19, 1993.

*Michael D. Banov, M.D.*

## **CONFERENCES**

Sachs GS, Stoll AL, Lafer B, Banov M, Thibeault A, Tohen M, Falk W, Zornberg G, Rosenbaum J, Cohen BM. *Bupropion versus Desipramine in Bipolar Depression. Double-blind comparison of acute and maintenance effects.* Presented at the Second International Conference on Refractory Depression, Amsterdam, The Netherlands, June 24-26, 1992.

## **PROFESSIONAL AFFILIATIONS**

American Psychiatric Association - 1990 to present

Georgia Psychiatric Association 1994 to present

Massachusetts Psychiatric Association - 1990 to 1994

American Medical Association - 1989 to present

## **REFERENCES**

Available on request.